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Major Confounders May Influence  
Multivariate Analysis in a Single-Center 
Observational Study
To the Editor:
In a recent issue of Critical Care Medicine, we read with great interest the article by Bayer et al (1) on the effect of vol-ume replacement using hydroxyethyl starch (HES), gelatin, 
and Ringer’s acetate in cardiac surgical patients. Although the 
number of patients being analyzed is highly impressive, there 
are several substantial limitations which need to be addressed.
First, Bayer et al (1) need to be congratulated that they 
realized to start this sequential prospective analysis in 2004. 
This was 2 years before the data of the Efficacy of Volume 
Substitution and Insulin Therapy in Severe Sepsis trial (2) 
were unblinded. In contrast, it is difficult to understand, why 
patients had to be retrospectively identified in the Patient Data 
Monitoring  System in their prospective observational trial.
Collecting data over many years at a single center inevita-
bly results in serious confounders. Between 2004 and 2010, 
perioperative management in cardiac surgical patients devel-
oped substantially, especially management of blood transfu-
sion changed from liberal to a restrictive strategy based on the 
findings by Murphy et al (3) that there is a significant trans-
fusion-related mortality in transfused patients. Interestingly, 
according to the data presented, there was no change in RBC 
transfusion over time. Additionally, management of coagula-
tion changed from a fresh frozen plasma-based regimen to a 
point-of-care-based, goal-directed therapy, including more 
clotting factors and fibrinogen. Last but not least, operating 
techniques in cardiac surgery went from invasive to minimal 
invasive and patients being operated presented in a higher age 
group with a more comorbidities, and progressively more valve 
surgery was performed over the three study periods.
In addition, there were four different heads of department 
in cardiac surgery at the University Hospital in Jena between 
2004 and 2010 including different teams and techniques, as 
well as three different interim heads of department. Therefore, 
a total of seven different cardiac surgical teams were active dur-
ing the study period, which was not mentioned in the article as 
a major confounding point.
None of the above factors,  such as type of surgery, surgeon, 
perioperative management, coagulation management, and 
Society of Parenteral and Enteral Nutrition 2013, increased pro-
tein intake up to the recommended 2 g/kg/d provoked no clini-
cal benefit and increased the need for renal replacement therapy 
in the first adequately powered RCT studying different protein 
doses in critical illness (https://www.anzctr.org.au/Trial/Regis-
tration/TrialReview.aspx?ACTRN=12609001015235).
The hypothetical potential for improved tissue repair 
and immunological response with enhanced protein intake 
early in critical illness is refuted by clinical results. First, early 
PN provoked increased incidence and delayed recovery of 
 ICU-acquired muscle weakness, studied in 600 awake EPaNIC 
patients (7). Furthermore, microscopically, quadriceps muscle 
biopsy analysis indicated that the muscle weakness was not 
explained by muscle fiber size but by suppressed autophagy. 
Autophagy, a catabolic cellular household mechanism crucial 
for clearing of cellular damage and malfunctioning organelles, 
was clearly enhanced by late PN (7).
Second, none of the RCTs mentioned earlier (2–5) showed 
reduced incidence of new infections with enhanced feeding in 
the first week of critical illness. Even more, in EPaNIC, early 
PN provoked a dramatic increase in wound infections, air way 
infections, and septicemia (2). Whether this should be attrib-
uted to glucose rather than protein, lipids, or total energy dose 
remains speculative. Nevertheless, administered macronutrient 
doses and obtained blood concentrations are more likely to be 
important than the osmolarity in the IV bag prior to infusion.
In conclusion, the results of recent clinical, body composi-
tion and cell metabolism investigations all consistently ques-
tion the paradigm of improving outcome in ICU through 
attenuation of early catabolism. 
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transfusion of blood products were not included in the multi-
variate analysis. Clearly, these factors need to be included and 
the multivariate analysis needs to be repeated. The negative 
result on the use of gelatin was not present after the univariate 
but only after the incomplete multivariate analysis.
Apart from the lack of correction for the inevitable con-
founders, there are obvious inconsistencies in the data: first, 
500 mL of HES was used as cardiopulmonary bypass priming 
in the HES and gelatin periods. Therefore, a 7 mL/kg (ideal) 
body weight dose of HES in the gelatin period appears rea-
sonable. However, in the crystalloid period, 1,000 mL of HES 
was used as cardiopulmonary bypass priming. Despite identi-
cal body mass indices, the median dose of HES administrated 
was reported to be 8 mL/kg (ideal) body weight. This obvious 
discrepancy needs explanation. Second, in Table 3 in the article 
by Bayer et al (1), the different fluids administered are listed. It 
is very difficult to understand how a total of 16 (8–29) mL/kg 
(ideal) body weight of gelatin was administered in the gelatin 
period when at the day of surgery 0 (0–8) and on postoperative 
days 1–3, each day another 0 (0–7 to 0–0) mL/kg (ideal) body 
weight of gelatin was administered. This simply does not add 
up and thus needs explanation or recalculation of the data.
In summary, there is insufficient evidence presented in this 
single-center trial justifying the authors’ conclusion. In con-
trast to the findings of this trial, in a well-performed recent 
meta-analysis by Saw et al (4) based on 30 trials and more than 
2,700 patients, it was demonstrated that the use of gelatin was 
associated with a lower prevalence of acute renal failure when 
compared with HES and a comparable risk when compared 
with crystalloids in critically ill patients. 
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